Probiotic Lowered Alzheimer's Blood Marker in Six-Month Placebo-Controlled Trial

This is a randomized, double-blind, placebo-controlled trial, the standard design for testing whether an intervention works. Neither participants nor researchers knew who got the probiotic. The study enrolled 87 people from the Gwangju Alzheimer's Disease and Related Dementias cohort: 40 received the probiotic and 47 received placebo. All had early cognitive impairment.

The main result concerns plasma pTau181, a form of the tau protein measured in blood. Tau is a protein that builds up abnormally in Alzheimer's disease. Compared with placebo, the probiotic group showed a significant reduction in pTau181 (p < 0.001).

Two other blood markers, GFAP and NfL, stayed stable in the probiotic group. In the placebo group, both rose significantly over the 24 weeks (p = 0.014 and p = 0.041). The authors describe these as neuroinflammatory biomarkers.

The researchers also tested thinking and daily function. The probiotic group had improved scores on the Clinical Dementia Rating Sum of Boxes (p = 0.010), a clinician-rated scale. The authors say the change was driven mainly by the memory domain. The probiotic group also did better on two visuospatial tasks, Constructional Praxis (p = 0.036) and the Rey-Osterrieth Complex Figure copy (p = 0.027). These tasks involve copying drawings and shapes. Recall of those drawings was preserved in the probiotic group, while the placebo group declined significantly (p = 0.025).

The benefits were not broad. There were no significant between-group differences on the Mini-Mental State Examination, verbal memory or executive function scores. The authors conclude that the probiotic "selectively preserved" visuospatial cognition.

Several limits matter for anyone weighing this. The trial was small and short. It drew on one cohort. It measured blood markers, not brain scans, so it cannot show that tau tangles in the brain were reduced. The authors themselves call the findings preliminary and say further studies are needed to confirm the mechanisms.

ScienceAlert, which covered the study, reports that the product was a three-strain formulation including Bifidobacterium animalis, Limosilactobacillus fermentum and Levilactobacillus brevis. It also reports that the inflammation marker IL-1β fell more in the probiotic group. That outlet cautions that how probiotics might affect the brain through the gut is poorly understood, and that animal results do not always carry over to people. The coverage said 100 people were originally randomized, while the study abstract reports 87 randomized participants.

So is a probiotic worth considering for early memory concerns? This trial gives a reason to study the question, not an answer. It tested one specific formulation in one group, and the cognitive gains were limited to certain measures. A single small trial cannot show whether the effects last or matter in daily life.

The authors call for larger and longer trials that include tau and amyloid-beta PET brain imaging, to test how durable and clinically relevant the effects are. Whether visuospatial testing works as a meaningful endpoint is another open question.